DK3345613T5 - Sammensætning til anvendelse i behandling af cancer eller en angiogeneserelateret sygdom omfattende et fusionsprotein af et tumorpenetrerende peptid og et anti-vegf-middel - Google Patents
Sammensætning til anvendelse i behandling af cancer eller en angiogeneserelateret sygdom omfattende et fusionsprotein af et tumorpenetrerende peptid og et anti-vegf-middel Download PDFInfo
- Publication number
- DK3345613T5 DK3345613T5 DK16842324.2T DK16842324T DK3345613T5 DK 3345613 T5 DK3345613 T5 DK 3345613T5 DK 16842324 T DK16842324 T DK 16842324T DK 3345613 T5 DK3345613 T5 DK 3345613T5
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- treatment
- composition
- fusion protein
- related disease
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 230000033115 angiogenesis Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000000149 penetrating effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150123878 | 2015-09-01 | ||
| PCT/KR2016/009801 WO2017039358A1 (ko) | 2015-09-01 | 2016-09-01 | 종양 투과성 펩타이드와 향-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3345613T3 DK3345613T3 (da) | 2023-07-31 |
| DK3345613T5 true DK3345613T5 (da) | 2024-09-30 |
Family
ID=58188859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16842324.2T DK3345613T5 (da) | 2015-09-01 | 2016-09-01 | Sammensætning til anvendelse i behandling af cancer eller en angiogeneserelateret sygdom omfattende et fusionsprotein af et tumorpenetrerende peptid og et anti-vegf-middel |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10919947B2 (da) |
| EP (1) | EP3345613B1 (da) |
| JP (1) | JP6893928B2 (da) |
| KR (1) | KR102128966B1 (da) |
| CN (1) | CN108348575B (da) |
| AU (1) | AU2016317882B2 (da) |
| BR (1) | BR112018004078A2 (da) |
| CA (1) | CA2996937C (da) |
| DK (1) | DK3345613T5 (da) |
| ES (1) | ES2951260T3 (da) |
| FI (1) | FI3345613T3 (da) |
| MX (1) | MX395266B (da) |
| RU (1) | RU2727238C2 (da) |
| SI (1) | SI3345613T1 (da) |
| WO (1) | WO2017039358A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US11066465B2 (en) | 2015-12-30 | 2021-07-20 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR101948238B1 (ko) | 2016-08-19 | 2019-02-14 | (주)케어젠 | 미녹시딜과 펩타이드의 결합체 |
| US20200165312A1 (en) * | 2017-06-28 | 2020-05-28 | Lg Household & Health Care Ltd. | Cosmetic composition for improving skin conditions comprising fusion protein including skin penetration enhancing peptide |
| WO2019016597A2 (en) * | 2017-07-18 | 2019-01-24 | Bioven 3 Limited | SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES |
| WO2019050326A1 (ko) * | 2017-09-08 | 2019-03-14 | 아주대학교산학협력단 | 뉴로필린 1 (neuropilin 1, nrp1)에 특이적으로 결합하는 펩타이드를 포함하는 조절 t 세포의 활성을 억제하기 위한 조성물 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN113164544A (zh) * | 2018-10-12 | 2021-07-23 | 三钰生物科技股份有限公司 | 双功能性融合蛋白及其用途 |
| EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
| CN112641928A (zh) * | 2019-10-11 | 2021-04-13 | 田中纯美 | 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途 |
| CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
| CN112522322A (zh) * | 2020-12-24 | 2021-03-19 | 深圳市人民医院 | 一种nrp1配体的修饰技术 |
| CN114028541A (zh) * | 2021-05-21 | 2022-02-11 | 中山大学 | Gdf2在制备改善肿瘤异常血管的药物中的用途 |
| CN118613280A (zh) * | 2022-01-14 | 2024-09-06 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 |
| KR102459219B1 (ko) * | 2022-03-31 | 2022-10-26 | 주식회사 셀아이콘랩 | 신규한 피부투과성 펩타이드, 이를 포함하는 피부 및 점막 조성물과 이의 용도 |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1946417A (zh) | 2003-12-05 | 2007-04-11 | 阿德内克休斯治疗公司 | 2型血管内皮生长因子受体的抑制剂 |
| RU2008106230A (ru) * | 2005-07-19 | 2009-08-27 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Средства проникновения через гематоэнцефалический барьер и внутрь клеток раковой опухоли мозга и способы их использования |
| NZ580530A (en) | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| EP2445536B1 (en) * | 2009-06-22 | 2016-06-08 | Burnham Institute for Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
| CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| EP4306123A3 (en) * | 2011-12-22 | 2024-04-17 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
| US9116159B2 (en) * | 2012-05-22 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | VEGF-A121 assay |
| KR101551299B1 (ko) * | 2013-05-23 | 2015-09-10 | 아주대학교산학협력단 | 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질 |
| KR101551306B1 (ko) * | 2015-03-23 | 2015-09-09 | 아주대학교산학협력단 | 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도 |
-
2016
- 2016-09-01 RU RU2018111390A patent/RU2727238C2/ru active
- 2016-09-01 FI FIEP16842324.2T patent/FI3345613T3/fi active
- 2016-09-01 BR BR112018004078-9A patent/BR112018004078A2/pt active Search and Examination
- 2016-09-01 MX MX2018002524A patent/MX395266B/es unknown
- 2016-09-01 CA CA2996937A patent/CA2996937C/en active Active
- 2016-09-01 SI SI201631730T patent/SI3345613T1/sl unknown
- 2016-09-01 ES ES16842324T patent/ES2951260T3/es active Active
- 2016-09-01 CN CN201680060604.2A patent/CN108348575B/zh not_active Expired - Fee Related
- 2016-09-01 DK DK16842324.2T patent/DK3345613T5/da active
- 2016-09-01 JP JP2018530461A patent/JP6893928B2/ja active Active
- 2016-09-01 EP EP16842324.2A patent/EP3345613B1/en active Active
- 2016-09-01 KR KR1020160112699A patent/KR102128966B1/ko active Active
- 2016-09-01 WO PCT/KR2016/009801 patent/WO2017039358A1/ko not_active Ceased
- 2016-09-01 AU AU2016317882A patent/AU2016317882B2/en not_active Ceased
-
2018
- 2018-03-01 US US15/909,086 patent/US10919947B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3345613B1 (en) | 2023-05-10 |
| AU2016317882A1 (en) | 2018-04-19 |
| MX395266B (es) | 2025-03-25 |
| SI3345613T1 (sl) | 2023-10-30 |
| RU2727238C2 (ru) | 2020-07-21 |
| US10919947B2 (en) | 2021-02-16 |
| DK3345613T3 (da) | 2023-07-31 |
| CN108348575A (zh) | 2018-07-31 |
| CA2996937C (en) | 2024-02-06 |
| CN108348575B (zh) | 2022-06-14 |
| CA2996937A1 (en) | 2017-03-09 |
| RU2018111390A3 (da) | 2020-01-31 |
| AU2016317882B2 (en) | 2021-01-28 |
| JP2018531989A (ja) | 2018-11-01 |
| RU2018111390A (ru) | 2019-10-04 |
| EP3345613A4 (en) | 2019-08-14 |
| KR102128966B1 (ko) | 2020-07-01 |
| BR112018004078A2 (pt) | 2018-12-11 |
| EP3345613A1 (en) | 2018-07-11 |
| FI3345613T3 (fi) | 2023-07-28 |
| KR20170027312A (ko) | 2017-03-09 |
| US20180237484A1 (en) | 2018-08-23 |
| WO2017039358A1 (ko) | 2017-03-09 |
| MX2018002524A (es) | 2018-11-09 |
| ES2951260T3 (es) | 2023-10-19 |
| JP6893928B2 (ja) | 2021-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3345613T5 (da) | Sammensætning til anvendelse i behandling af cancer eller en angiogeneserelateret sygdom omfattende et fusionsprotein af et tumorpenetrerende peptid og et anti-vegf-middel | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| DK3922279T3 (da) | Præparater til lægemiddelafgivelse og anvendelse heraf | |
| IL269150A (en) | Compositions and methods for treating cancer | |
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| DK3368555T3 (da) | Dobbeltfunktionsproteiner og farmaceutisk sammensætning omfattende disse | |
| DK3250237T3 (da) | Hemiasterlinderivater til konjugering og terapi | |
| DK3430027T3 (da) | Peptid til anvendelse ved immunterapi mod ikke-småcellet lungecancer og småcellet lungecancer | |
| PL3303632T3 (pl) | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze | |
| DK3515476T3 (da) | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer | |
| DK3368554T3 (da) | Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme | |
| IL269741A (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| EP3515420C0 (en) | PHARMACEUTICAL COMPOSITIONS FOR USE IN BLEPHARITIS THERAPY | |
| EP3551212A4 (en) | NEW RECOMBINATED KLOTHO PROTEINS AND COMPOSITIONS AND METHODS INCLUDING THEM | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| EP3518971A4 (en) | Antibody and protein therapeutic formulations and uses thereof | |
| SI3565828T1 (sl) | SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| DK3439663T3 (da) | Fremgangsmåder til behandling af pædiatriske cancere | |
| EP3581183A4 (en) | PHARMACEUTICAL COMPOSITION FOR ONCOTHERAPY | |
| DK3269733T3 (da) | Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler | |
| DK3532067T3 (da) | Liposomal formulering til anvendelse til behandling af cancer | |
| CL2021000623A1 (es) | Péptidos asociados a tumor y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346) |